ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1749

The Role of Mucosal-Associated Invariant T (MAIT) Cells in Lupus Dermatitis

Goh Murayama1, Asako Chiba2, Hirofumi Amano3, Ken Yamaji1, Naoto Tamura1 and Sachiko Miyake4, 1Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 2Juntendo Univ Sch of Med, Juntendo University School of Medicine, Tokyo, Japan, 3Department of Rheumatology and Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan, 4Immunology, Juntendo University School of Medicine, Tokyo, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: lupus dermatitis, mouse model and treatment, SLE, T cells

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Animal Models - Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate T cells that are restricted by MHC-related molecule-1 (MR1) and express a semi-invariant TCRa chain: Va7.2-Ja33 in humans and Va19-Ja33 in mice. Previously, we have demonstrated that MAIT cells played a protective role against experimental autoimmune encephalomyelitis, an animal model of human multiple sclerosis. We have found that MAIT cells are activated in patients with systemic lupus erythematosus (SLE) and that the activation state of MAIT cells correlated with SLE disease activity index (SLEDAI) score. Therefore, we conducted this study to clarify functions of MAIT cells in a lupus model by using FcgRIIB-/- Yaa mice.

Methods: FcgRIIB-/- Yaa mice were crossed to MR1 deficient mice lacking MAIT cells, and disease progression was compared between MR1-/- FcgRIIB-/- Yaa and FcgRIIB-/- Yaa mice. Serum anti-dsDNA antibody levels were measured by anti-dsDNA– ELISA Kit (Libis) and urinary microalbumin were evaluated by SIEMENS DCA 2000. At the time of sacrifice, the severity of nephritis and dermatitis were assessed by histologically. Haematoxylin-eosin staining of skin sections were graded on a scale of 1 to 3 for acanthosis; 1 to 2 for hyperkeratosis, interface liquefaction, inflammation, dermal cellularity, presence of dilated vessels with hemorrhage; 0 to 1 for ulcer or erosion. For statistical analysis, all data were analyzed using GraphPad Prism (GraphPad), and differences between the groups were assessed using the Mann-Whitney U test. The significance level was set at p < 0.05. Associations between 2 variables were analyzed using Spearman correlation.

Results: MR1-/- FcgRIIB-/- Yaa mice showed exacerbated inflammation in the skin lesions. There was a high degree of inflammatory cells infiltration into the skin and a significant worsening of dermatitis score in MR1-/- FcgRIIB-/- Yaa mice compared to FcgRIIB-/- Yaa mice. There were no differences in serum levels of anti-dsDNA antibody, proteinuria, and kidney histopathology.

Conclusion: The present study demonstrates that dermatitis was exacerbated in MR1-/- FcgRIIB-/- Yaa mice, indicating that MAIT cells may have a suppressive effect on skin inflammation. Because MAIT cells have recently been found in human skin, MAIT cells may be useful therapeutic targets for the treatment of lupus dermatitis.


Disclosure: G. Murayama, None; A. Chiba, None; H. Amano, None; K. Yamaji, None; N. Tamura, None; S. Miyake, ASUBIO PHARMA CO., LTD, 2,TAIHO PHARMACEUTICAL CO., LTD., 5.

To cite this abstract in AMA style:

Murayama G, Chiba A, Amano H, Yamaji K, Tamura N, Miyake S. The Role of Mucosal-Associated Invariant T (MAIT) Cells in Lupus Dermatitis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-role-of-mucosal-associated-invariant-t-mait-cells-in-lupus-dermatitis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-role-of-mucosal-associated-invariant-t-mait-cells-in-lupus-dermatitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology